What is the clinical evidence from this study?

Study design: Review. Population: Thrombosis. Intervention: Aspirin.

What question did this study set out to answer?

To review the biochemical mechanisms of aspirin's antiplatelet action and evaluate its optimal dosing and limitations in the treatment and prevention of arterial thrombosis.

August 1, 1997Seminars in Thrombosis and Hemostasis

Aspirin and Platelets: The Antiplatelet Action of Aspirin and Its Role in Thrombosis Treatment and Prophylaxis

View Full Paper

Ask AI

Bookmark

Key result

Aspirin acts as an antithrombotic by irreversibly inhibiting platelet COX-1, with 100 mg/day sufficient for coronary thrombosis prevention, though higher doses may be needed for other circulations.

Design

Review

Authors

KSKarsten SchrörCross-Cutting Cardiology

Discussion

Member takes

Implication

Confirms low-dose aspirin for coronary prevention; leaves open optimal dosing for other circulations and bleeding-risk balance.

Key Points

To review the biochemical mechanisms of aspirin's antiplatelet action and evaluate its optimal dosing and limitations in the treatment and prevention of arterial thrombosis.
Evaluated the biochemical mechanism of platelet cyclooxygenase (COX-1 and COX-2) acetylation and thromboxane synthesis inhibition by acetylsalicylic acid.
Analyzed clinical dosage requirements across coronary, cerebral, and peripheral circulations alongside mechanisms of platelet resistance.
Aspirin irreversibly inhibits platelet thromboxane production by acetylating serine529 of COX-1, demonstrating 150- to 200-fold higher potency for COX-1 than for COX-2.
A dose of 100 mg/day prevents coronary thrombosis, whereas higher dosages may be required for cerebral and peripheral circulations, with all therapeutic doses conferring an increased bleeding risk.
Prostaglandin-independent activation mechanisms, including shear stress and ADP signaling, are not inhibited by aspirin and contribute to observed antiplatelet resistance.

Structured PICO

Intervention

Aspirin (acetylsalicylic acid)

Aspirin acts as a potent, irreversible inhibitor of COX-1 to prevent arterial thrombosis, but its clinical use requires balancing antithrombotic benefits against inherent bleeding risks.

Limitations

Any effective antiplatelet dose of aspirin is associated with an increased risk of bleeding
Platelet activation caused by other factors remains unchanged and might result in aspirin resistance
No sparing of endothelial prostacyclin synthesis in clinical conditions of atherosclerotic endothelial injury

Cite This Study

Karsten Schrör (1997) conducted a review in Thrombosis. Aspirin was evaluated. Aspirin acts as an antithrombotic by irreversibly inhibiting platelet COX-1, with 100 mg/day sufficient for coronary thrombosis prevention, though higher doses may be needed for other circulations.

synapsesocial.com/papers/6a0cfbb1b31ab1d6e01e7690 https://doi.org/10.1055/s-2007-996108

Topics

Dual antiplatelet therapy

View Full Paper

Ask AI

Bookmark

Aspirin and Platelets: The Antiplatelet Action of Aspirin and Its Role in Thrombosis Treatment and Prophylaxis

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Topics

Aspirin and Platelets: The Antiplatelet Action of Aspirin and Its Role in Thrombosis Treatment and Prophylaxis

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Also Consider

Topics

Also Consider